TargetBeta
TFPI
tissue factor pathway inhibitor · also EPI, TFI, TFPI1, LACI
2 programs in company-led studies act on TFPI, from 2 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| andexanet alfarule | AstraZeneca | phase 4 | 140 running | – | ChEMBL |
| marstacimabrule | Pfizer | phase 3 | 104 running | – | ChEMBL |
Conditions their studies are in
- Hemophilia A, 1 program
- Hemorrhage, 1 program
- Thrombosis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- May 5, 2027marstacimab · Pfizer · phase 3 · NCT06703606
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.